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Abstract
HLA-DR, an MHC class II molecule that mediates antigen presentation, is a favourable prognostic indicator in colorectal 
cancer (CRC). However, the dynamics and location of HLA-DR expression during CRC development are unclear. We aimed 
to define HLA-DR expression by immunohistochemistry in colorectal epithelium and stromal tissue at different stages of 
cancer development, assessing non-neoplastic colorectal adenocarcinoma–adjacent tissue, adenomas and carcinoma tissues, 
and to associate HLA-DR levels with clinical outcomes. Patients with higher than median HLA-DR expression survived at 
least twice as long as patients with lower expression. This association was significant for HLA-DR staining in the colorectal 
carcinoma epithelium (n = 152, p = 0.011, HR 1.9, 95% CI 1.15–3.15) and adjacent non-neoplastic epithelium (n = 152, 
p < 0.001, HR 2.7, 95% CI 1.59–4.66), but not stroma. In stage II cases, however, the prognostic value of HLA-DR expression 
was significant only in adjacent non-neoplastic tissues, for both epithelium (n = 63, p = 0.015, HR 3.6, 95% CI 1.279–10.25) 
and stroma (n = 63, p = 0.018, HR 5.07, 95% CI 1.32–19.49). HLA-DR was lower in carcinoma tissue compared to matched 
adenomas (n = 35), in epithelium (p < 0.01) and stroma (p < 0.001). HLA-DR was further reduced in late-stage carcinoma 
(n = 101) compared to early stage (n = 105), in epithelium (p < 0.001) and stroma (p < 0.01). HLA-DR expression was lower 
(p < 0.05) in the adjacent non-neoplastic epithelium of patients with cancer recurrence. We demonstrate a progressive loss 
of HLA-DR in epithelial and stromal tissue compartments during CRC development and show prognostic ability in carci-
noma–adjacent non-neoplastic tissues, highlighting the importance of this molecule in the anti-cancer immune response. 
These findings may have wider implications for immunotherapeutic interventions.
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Introduction
Colorectal cancer (CRC) is the third most common type of 
cancer worldwide and the third leading cause of cancer mor-
tality [1]. Despite recent advances in treatment and patho-
logical staging, many CRC patients still experience cancer 
recurrence. Most notably, 25% of stage I/II cancers detected 
at the node-negative, metastasis-negative stage experience 
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cancer recurrence [2]. Therefore, there is an urgent need to 
improve current prognostic and surveillance strategies for 
CRC patients and to better understand the factors underlying 
disease progression and recurrence. In recent years, certain 
immune markers, such as CD3, CD8 and CD45RO, have 
been shown to play a favourable prognostic role in CRC, 
highlighting the requirement for effective immune responses 
for cancer elimination [3–5]. The prognostic potential of 
other immune markers upstream of the adaptive immune 
response is also of great interest, such as the antigen pres-
entation molecule HLA-DR.
HLA-DR is a major histocompatibility complex (MHC) 
class II antigen presentation molecule, critical for the acti-
vation of lymphocytes and the orchestration of adaptive 
immune responses. HLA-DR is normally expressed on 
antigen-presenting cells including monocytes, macrophages, 
dendritic cells and B cells, but expression can be induced on 
epithelial cells and tumour cells in response to inflammatory 
conditions [6–8]. MHC class II antigen presentation mole-
cules are responsible for presentation of exogenous antigens 
to  CD4+ helper T cells. Unsurprisingly, HLA-DR expression 
in tumours has been positively associated with enhanced 
lymphocytic infiltration [9–12]. HLA-DR has been used 
as a surrogate marker of immune competence in various 
clinical studies, and its loss in circulation has been linked 
with susceptibility to post-surgical infection [13] and sepsis 
[14]. The mechanism that drives this reduction in monocyte 
HLA-DR is not well understood, but this phenomenon has 
been described in response to even minor surgeries. It has 
been suggested that restoration of HLA-DR expression, as 
opposed to the initial loss itself, may be a more useful pre-
dictor of post-operative complications [15].
In the neoplastic setting, HLA molecules have demon-
strated a largely favourable prognostic role in gastrointes-
tinal cancers, such as oesophageal adenocarcinoma [16], 
cancer of the larynx [17], gastric cancer [18] and CRC [19, 
20]. It has been proposed that the improved patient survival 
observed in HLA-DR expressing tumours reflects an active 
anti-tumour immune response, as evidenced by the correla-
tion between HLA expression and intra-tumoral lymphocytic 
infiltration [11, 19]. Despite previous descriptions of HLA 
molecule expression in tumours and its clear clinical impli-
cations, few studies have evaluated HLA-DR expression 
specifically during cancer development, and fewer still have 
defined expression within different tissue compartments, i.e. 
epithelium versus stromal regions, instead giving general-
ised staining scores.
This study aimed to evaluate changes in HLA-DR 
expression during development of CRC from colorectal 
adenomas and adenocarcinomas at early and late stages 
and to define expression within both epithelial and stromal 
tissue compartments, and in both carcinoma and carci-
noma–adjacent tissues. HLA-DR expression was evaluated 
by immunohistochemistry using archival formalin-fixed, 
paraffin-embedded colorectal tissue resections. We aimed to 
investigate HLA-DR loss in CRC cancer progression and to 
determine whether this is a universal phenomenon, common 
to all carcinomas, or whether HLA-DR loss only occurred 
in certain patients. We were also interested in determining 
which colorectal tissue compartments expressed the highest 
levels of HLA-DR and which experienced most HLA-DR 
loss. Finally, we were interested in determining whether 
HLA-DR expression still showed a prognostic ability even 




For this study, formalin-fixed paraffin-embedded colorec-
tal tissue specimens (all histologies) were collected from 
patients undergoing surgical resection or polypectomy at 
St Vincent’s University Hospital, Dublin. Tissue regions 
of interest were defined by a pathologist (AAM). Carci-
noma–adjacent non-neoplastic colorectal tissue specimens 
were also collected from areas at least 10 cm away from 
the primary carcinoma. Tumour specimens were sampled 
from the primary tumour site. This study was performed 
in adherence to the Declaration of Helsinki ethical princi-
ples for medical research involving human subjects. Writ-
ten informed consent was obtained in accordance with local 
institutional ethical guidelines. Full ethical approval to con-
duct this study was grant by the St. Vincent’s University 
Hospital ethics committee.
Adenomas
Adenomas (isolated, synchronous or contiguous) were col-
lected from a cohort of n = 79 patients (n = 25 male, mean 
age 70.2 [range 48–86]) undergoing treatment at St Vincent’s 
University Hospital, Dublin, between the years 1994–2006. 
Percentage HLA-DR-positive staining scores were available 
for matched carcinoma specimens for n = 33 synchronous 
and n = 35 contiguous adenomas. Synchronous adenomas 
were defined as adenomas separate from the main carcinoma 
identified in the resection specimens, while contiguous ade-
nomas were defined as residual adenoma contiguous with 
the primary carcinoma.
CRC cohort—all stages
Carcinoma and adjacent tissues were collected from a cohort 
of n = 152 patients diagnosed with CRC who underwent 
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surgical resection at St Vincent’s Hospital, Dublin. This 
cohort was sub-divided by stage using the American Joint 
Committee on Cancer TNM staging system for subsequent 
studies, details as follows.
CRC stage II cohort
As detailed in Table 1, a cohort of n = 77 CRC carcinomas 
(n = 34 female; n = 43 male) with a diagnosis of stage II 
was compiled from retrospective archival tissue collected 
between 1991 and 2001 from patients treated at St Vincent’s 
University Hospital, Dublin. Median patient age at diagnosis 
was 73.5 (range 48–91). Patients were followed from the 
date of diagnosis until death or median follow-up time of 
6.1 years. Incidence of all deaths and disease recurrence was 
recorded during the follow-up period. Overall survival was 
defined as time from diagnosis until death, from any cause.
CRC late‑stage cohort
As detailed in Table  2, a cohort of n = 75 CRC carci-
noma patients (n = 40 male; n = 35 female) with a diag-
nosis of stage III or IV (Duke’s C and D) was compiled 
from retrospective archival tissue collected between from 
patients treated at St Vincent’s University Hospital, Dub-
lin. Median patient age at diagnosis was 65.6 years (range 
25.4–83.8 years). Patients were followed from the date of 
diagnosis until death or median follow-up time of 2.04 years. 
Overall survival was defined as time from diagnosis until 
death, from any cause.
HLA‑DR immunohistochemistry analysis using 
tissue microarrays
Haematoxylin and eosin (H&E)-stained slides from forma-
lin-fixed, paraffin-embedded biopsies were used to define 
areas of adenoma, carcinoma or adjacent non-neoplastic 
tissues by a pathologist (AAM). The areas of interest on 
the diagnostic biopsy blocks were marked by a patholo-
gist (AAM), four 0.6 mm cores were taken from the tis-
sue blocks, transferred to a recipient block using a Tissue 
Microarrayer (Beecher Instruments), and tissue microarrays 
(TMAs) were constructed and pathology of the tissue re-
evaluated prior to antibody staining. Four cores were taken 
from each individual tissue type (tumour, polyp, etc.), and 
a 4-μM section from each was included on the TMA slide 
in order to reduce sampling errors, and to check that stain-
ing patterns were consistent within each tissue area. Each 
section was scored individually; then these four scores were 
averaged to give an overall score. A consistent staining pat-
tern was observed for each tissue area sampled, with the 
majority of scores being either identical, or falling within 1 
Table 1  Stage II CRC patient cohort
*Denotes missing values due to tissue degradation or missing tissue 
microarray cores
Parameter Category Frequency Total
Gender Female 34 77
Male 43
Lymphovascular invasion Positive 15 (1 mural) 77
Negative 46
Not reported 16















Normal stroma 61.1% 77
Carcinoma stroma 49.3% 77
Table 2  Late-stage patient cohort
*Denotes missing values due to tissue degradation or missing tissue 
microarray cores
Parameter Category Frequency Total
Gender Male 40
Female 35 75



















Normal stroma 60.7% 72*
Carcinoma stroma 36% 72*
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scoring increment. Different tissue types were run together 
on the same TMA slide, in order to minimise technical arte-
facts. Four-micrometre sections were cut and mounted onto 
Super Frost Plus adhesive slides (Menzel-Glaser, Germany). 
Immunohistochemistry was performed utilising a Vectastain 
Elite ABC HRP kit (Vector Laboratories, USA) or DAKO 
ChemMate Envision kit (Dako, Denmark), as per manufac-
turer’s instructions. Tissue staining was compared between 
TMA slides to ensure similar staining patterns, and intensi-
ties were observed between kits. All tissue microarray sec-
tions for each patient cohort were processed and stained on 
the same day at room temperature.
Staining was performed as previously described [16], 
using the monoclonal mouse anti-HLA-DR IgG (clone TAL 
1B5, Abcam, Cambridge, UK) primary antibody. To control 
for potential cross reactivity, whole full-face tissue sections 
were incubated with PBS in the absence of primary anti-
body and/or secondary antibody. Slides were incubated with 
primary antibody for 1 h, biotinylated secondary antibody 
for 30 min, avidin–biotin complex for 30 min and diamin-
obenzidine (DAB) substrate for 2–15 min. DAB was rinsed 
off slides upon colour development and haematoxylin added 
for 30 s. Slides were dehydrated and mounted using DPX. 
Images were taken using a ScanScope GL digital slide scan-
ner using Aperio ImageScope software (Aperio Technolo-
gies, USA), and immunoreactivity was assessed digitally 
under 40X magnification in a semi-quantitative manner for 
visible HLA-DR expression by observers (MRD, JJP, AJM) 
who were blinded to the pathology and clinical outcome of 
all patients in the study. Epithelium was defined by colum-
nar shape, and all other non-epithelial tissue was defined as 
stroma; both epithelial and stromal cells were evaluated for 
both percentage positivity of cytoplasmic staining. HLA-DR 
positivity was evaluated as 0%, 10%, 25%, 50%, 75%, 90% 
or 100% of total visible tissue compartment. The scoring 
was undertaken by consensus evaluation (MRD, JJP, AJM), 
and scores from all observers were then averaged to create 
a final consensus score. Cohorts were divided into HLA-
DR high and low populations by median positivity scores. 
We adhered to the REMARK guidelines [21] for reporting 
prognostic markers in order to allow reproducibility of our 
findings.
Statistical analyses
Statistical analyses were performed and graphed using 
Prism GraphPad (Version 5) and IBM SPSS Statistics 
(Version 24). For survival analysis, the median percentage 
score of the cohort was chosen as a cut-off value in order 
to segregate HLA-DR high (> median) and low (0-median, 
inclusive) staining levels. Survival was analysed utilising 
Kaplan–Meier survival analysis (log-rank (Mantel–Cox)). 
Paired tests were used for matched tissues from the same 
donors, as appropriate. Differences of p < 0.05 (*), p < 0.01 
(**) and p < 0.001 (***) were considered statistically 
significant.
Results
HLA‑DR expression is associated with a longer 
survival time when measured in carcinoma 
and carcinoma–adjacent epithelium, 
but not in stroma
We first investigated whether HLA-DR expression in epi-
thelial and stromal tissue compartments was linked with 
patient survival, in carcinoma and carcinoma–adjacent 
colorectal tissues at all tumour stages. HLA-DR-positive 
expression was assessed in a cohort of n = 152 CRC patients 
at all carcinoma stages (demographics as per Tables 1 and 
2). Patients were assigned to HLA-DR high or low groups, 
using median expression level as a cut-off, and associations 
were tested by log rank (Mantel–Cox) tests and estimated 
using Kaplan–Meier survival curves. As shown in Fig. 1, 
we observed a longer survival time in patients expressing 
high levels of HLA-DR in the tissue epithelium, both in the 
carcinoma epithelium (Fig. 1a) (p = 0.012, HR 1.91, 95% 
CI 1.2–3.2, n = 72) and in carcinoma–adjacent epithelia 
(Fig. 1b) (p < 0.001, HR 2.72, 95% CI 1.6–4.7, n = 67), com-
pared to those with lower than median expression (n = 80 
and n = 85, respectively). No significant associations were 
observed when HLA-DR expression in the carcinoma stroma 
(Fig. 1c) (p = 0.11) or carcinoma–adjacent stroma (Fig. 1d) 
(p = 0.5) was analysed, however. Cox regression multivari-
ate analyses also demonstrated prognostic ability of other 
parameters, with T stage 4 (p = 0.02, HR 2), moderate dif-
ferentiation (p = 0.001, HR 2.8) and poor differentiation 
stage (p < 0.000, HR 7), and carcinoma size (p = 0.03, HR 
1.15), all predicting increased risk of disease-associated 
death (Table 3).
HLA‑DR expression diminishes during CRC 
development
The percentage of HLA-DR-positive expression was evalu-
ated in CRC carcinomas and synchronous (n = 33) or contig-
uous (n = 35) adenomas from matched CRC patients (Fig. 2) 
to assess changes in HLA-DR expression at different stages 
in carcinoma development. HLA-DR expression was lower 
in carcinoma epithelium compared to the epithelium of con-
tiguous matched adenomas (p < 0.01), but no difference in 
expression was observed when carcinomas were compared 
with synchronous adenomas (Fig. 2b). HLA-DR expression 
was lower in the CRC carcinoma stroma compared to that 
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of both synchronous (p < 0.001) and contiguous adenomas 
stroma (p < 0.001) (Fig. 2c).
We next aimed to assess whether HLA-DR expression 
was altered across different stages of cancer development, 
from pre-neoplastic, to early-stage to late-stage carcinomas. 
HLA-DR was therefore assessed in epithelial and tumour 
areas of a cohort of mixed adenomas (isolated, synchronous 
and contiguous adenomas, n = 79), early-stage CRC carcino-
mas (n = 105, stage I or II) and late-stage CRC carcinomas 
(n = 101, stage III or IV) (Fig. 2d, e). In the epithelial com-
partment (Fig. 2d), HLA-DR expression was lower in late-
stage carcinomas compared to early stage (p < 0.001) and 
adenomas (p < 0.001), but no significant difference was 
observed between adenomas and early-stage carcinomas. 
In the stromal compartment (Fig. 2e), HLA-DR expres-
sion was progressively reduced when late-stage carcinomas 
were compared with early-stage carcinomas (p < 0.01) or 











Carcinoma Epithelium *P=0.011 Adjacent Epithelium ***P<0.001
Carcinoma Stroma P=0.112 Adjacent Stroma P=0.499
P Value Hazard Rao 95% C.I.
Overall Survival 0.012 1.906 1.15-3.15
P Value Hazard Rao 95% C.I.
Overall Survival 0.000 2.722 1.59-4.66
P Value Hazard Rao 95% C.I.
Overall Survival 0.114 1.483 0.91-2.42
P Value Hazard Rao 95% C.I.
Overall Survival 0.499 1.183 0.73-1.93
A
Fig. 1  HLA-DR expression is associated with longer overall survival 
when measured in carcinoma and carcinoma–adjacent epithelium, 
but not in stroma. Data from n = 152 CRC patients at all stages were 
combined and analysed utilising Kaplan–Meier survival analysis (log 
rank (Mantel–Cox)). HLA-DR expression profiles were divided into 
high and low categories, using median expression as a cut-off. High 
HLA-DR expression in the epithelial compartments of a carcinoma 
(HR 1.9, p = 0.011, high n = 72, low n = 80) and b matched carci-
noma–adjacent normal tissue (HR 2.7, p < 0.001, high n = 67, low 
n = 85) was associated with improved overall survival. No statistically 
significant associations were detected between survival and HLA-DR 
expression profiles in stromal tissues from either c carcinoma stroma 
(p = 0.112, high n = 73, low n = 79) or d matched carcinoma–adja-
cent normal tissue stroma (p = 0.499, high n = 67, low n = 85). Cox 
regression multivariate analysis demonstrated that, in addition to low 
HLA-DR expression, T stage 4 (p = 0.02), moderate differentiation 
stage (p = 0.001) and poor differentiation stage (p < 0.000) were all 
predictors of poor survival, associated with twofold, 2.8-fold and sev-
enfold increases in disease-associated death, respectively. *p < 0.001, 
***p < 0.0001
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expression was diminished in late-stage carcinomas when 
compared to adenomas (p < 0.001).
HLA‑DR expression is lower in late‑stage CRC stroma 
compared to carcinoma–adjacent stroma
Having observed a significant reduction in HLA-DR expres-
sion in carcinoma tissues in later-stage carcinomas compared 
to early-stage, we were interested in investigating whether 
carcinoma–adjacent tissues were similarly affected. HLA-
DR expression was assessed across the epithelial and stro-
mal compartments of n = 76 early-stage (stage II) (Fig. 3a) 
and n = 72 late-stage (stage III and IV) (Fig. 3b) CRC car-
cinomas and adjacent non-carcinoma tissues. HLA-DR 
expression was lower in CRC carcinoma stroma compared 
to non-carcinoma stroma (p < 0.001), regardless of cancer 
stage. However, no significant difference was noted between 
HLA-DR expression in the epithelial compartments of carci-
noma versus carcinoma–adjacent tissue, at neither early nor 
late stages. The profound stage-dependent loss of epithelial 
HLA-DR expression observed in Fig. 2 was also recapitu-
lated in this cohort, with adjacent non-carcinoma tissue epi-
thelium also exhibiting significantly lower HLA-DR expres-
sion in late-stage patients in comparison with early stage.
Fig. 2  HLA-DR expres-
sion diminishes as adenomas 
progress to carcinomas and 
advance in stage. HLA-DR 
expression was visualised by 
immunohistochemistry, as 
shown for a single representa-
tive donor (a) and percentage 
positive expression was scored 
for colorectal tissue epithe-
lium and stroma in a cohort of 
synchronous (n = 29–33) or con-
tiguous (n = 33–35) adenomas 
and matched carcinomas (b, c) 
and adenomas (n = 79), early-
stage (stage I/II, n = 103–105) 
and late-stage carcinomas (stage 
III/IV, n = 92–101) (d, e). Data 
were analysed using paired t 
test or one-way ANOVA as 
appropriate (Kruskal–Wallis test 
followed by Dunn’s multiple-
comparison test). **p < 0.01, 
***p < 0.001
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HLA‑DR clinical correlations in stage II CRC 
Given the significant expression differences observed 
between stage II carcinomas and adjacent tissues, we 
next investigated whether HLA-DR was linked with a set 
of clinical outcomes in early-stage carcinomas. HLA-DR 
percentage positivity was assessed in a cohort of n = 77 
stage II CRC carcinomas (Table 1), and associations were 
tested with carcinoma recurrence (data available for n = 61 
patients), lymphovascular invasion status (n = 61), number 
of carcinoma buds (n = 30) and carcinoma differentiation 
stage (n = 66). HLA-DR expression was compared within 
the stage II CRC cohort between patients who experienced 
carcinoma recurrence (n = 14) versus those who did not 
(n = 47) (Fig. 4). HLA-DR was higher in the epithelium of 
patients with no recurrence compared to those with recur-
rence (p < 0.05); however, this was only observed in carci-
noma–adjacent colorectal tissue (Fig. 4a), and not in carci-
noma tissues (Fig. 4b). No significant differences were noted 
within the respective stromal compartments. No significant 
associations were noted between HLA-DR expression and 
lymphovascular invasion status or number of carcinoma 
buds (Supplementary Figs. 1 and 2).
HLA‑DR expression in stage II carcinoma–adjacent 
tissue is positively associated with survival time
HLA-DR expression by carcinoma or carcinoma–adjacent 
tissue was assessed with respect to survival time in a cohort 
of n = 77 early-stage (stage II) CRC patients (Table 1). 
Patients were assigned to HLA-DR high or low groups, 
using median expression as a cut-off. Survival times were 
assessed by log rank (Mantel–Cox) tests and estimated 
using Kaplan–Meier survival curves, as shown in Fig. 5. We 
observed that individuals with high HLA-DR expression in 
carcinoma–adjacent tissues survived longer than those with 
low expression, both in the tissue epithelium (p = 0.015, 
HR 3.62, 95% CI 1.3–10.3) and stroma (p = 0.018, HR 
5.07, 95% CI 1.3–19.5), (Fig. 5a, b). No significant differ-
ence was noted in the CRC carcinoma epithelium or stroma, 
however (Fig. 5c, d). Therefore, HLA-DR only displayed 
prognostic ability in early-stage CRC when measured in car-
cinoma–adjacent tissues, but not in early-stage carcinomas 
themselves (Table 3). 
Discussion
Previous studies have demonstrated a significant association 
between MHC class II expression in CRC tumours and over-
all survival time [11, 19, 20, 22, 23], lower recurrence [24, 
25], lower tumour stage [26], lymphocytic infiltration and 
microsatellite instability [23]. However, there is a lack of 
consistency in the literature regarding these findings in CRC, 
with several of these studies showing contradictory results, 
such as the level of HLA-DR in CRC tumours which has 
been reported as being expressed by between 23 and 60.1% 
of CRC tumours, depending on the study. A possible expla-
nation for these conflicts may lie in the differences in tissue 
scoring methodology and reporting approaches, as well as 
use of MHC class II antibodies with different specificities. 
For example, Matsushita and colleagues analysed HLA-DR 
using the HU-20 antibody in 51 snap-frozen CRC tumours 
and adjacent tissues and defined HLA-DR positivity as cases 
where > 10% cancer cells were strongly stained [20]. Scon-
nochiaet al., however, used a LGII-612.14 antibody specific 
for all MHC class II molecules (HLA-DR, HLA-DP and 
HLA-DQ) to stain formalin-fixed paraffin-embedded tissue, 
and defined positivity as > 15 positive cells observed in a 
field count of 100 cells [19]. In this study, we focused on 
Fig. 3  HLA-DR expression is lower in CRC carcinomas compared 
to carcinoma–adjacent tissue, but only in the stromal compartment. 
HLA-DR expression was higher in the stroma of carcinoma–adja-
cent tissues compared to matched carcinomas, for both early-stage 
a (p < 0.001, n = 76) and late-stage b (p < 0.001, n = 72) CRC cases, 
whereas no statistically significant difference was detected within the 
epithelium, regardless of stage. Wilcoxon matched paired t tests; bars 
denote mean ± SEM. ***p < 0.001
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assessing expression of the MHC class II molecule HLA-DR 
(clone TAL 1B5) in a tissue microarray constructed from 
multiple tumour samples from an archival cohort of forma-
lin-fixed paraffin-embedded colorectal carcinoma cores, and 
extended analyses to include patient-matched pre-malignant 
adenomas and non-neoplastic carcinoma–adjacent tissues, 
evaluating expression in both epithelial and stromal regions. 
We reported overall percentage positivity for the epithelium 
and stromal compartments, taking an average reading of 
three entire 0.6 mm fields into account.
In agreement with previous studies in CRC [11, 19, 20, 
22, 23], we observed a significant association between 
higher HLA-DR expression in CRC carcinomas and over-
all survival, particularly in the epithelial tissue compart-
ment. We also observed that higher HLA-DR expression 
in carcinoma–adjacent epithelium was positively associ-
ated with overall survival time, and this finding was par-
ticularly evident when stage II carcinomas were assessed. 
Carcinoma–adjacent epithelium also showed higher HLA-
DR expression in patients who had not experienced cancer 
recurrence, signifying an important prognostic capability 
of non-carcinoma tissues. Other recent studies have also 
demonstrated the prognostic importance of extra-tumoral 
tissues, in different cancer settings. Prasanna and colleagues 
observed significant prognostic ability of ten radiographic 
features (so-called radiomics) in the peri-tumoral areas of 
glioblastoma [27]. Genetic and molecular analyses of carci-
noma–adjacent histologically normal breast tissue revealed 
RNA signatures associated with significantly worse 10-year 
survival in estrogen receptor-positive breast cancer [28]. 
Therefore, it is plausible that immune markers outside CRC 
tissues demonstrate prognostic potential. Why this is par-
ticularly apparent in early-stage carcinomas is currently 
unclear but may reflect early immune cell trafficking into 
carcinomas. Further work is required to fully assess the 
impact of HLA-DR expression patterns in relation to clinical 
outcomes. We sampled expression in polyp and carcinoma 
cores and found relatively homogenous expression between 
cores; however, expression may be different at the invasive 
margins, and perhaps even more informative. Foukas and 
colleagues report differences in HLA-DR expression in lung 
cancer at different distances to the tumour and posit that this 
Fig. 4  HLA-DR expression is 
lower in carcinoma–adjacent 
epithelial tissue in stage II CRC 
patients who experience carci-
noma recurrence and highest in 
poorly differentiated carcino-
mas. HLA-DR expression was 
lower (p < 0.05) in the epithe-
lium of stage II CRC patients 
experiencing a carcinoma 
recurrence (n = 14) compared 
to those with no recurrence 
(n = 47). This difference was 
only observed in the epithe-
lium of carcinoma–adjacent 
tissue (a), and not in carcinoma 
epithelium or stroma (b). HLA-
DR expression was highest 
in CRC carcinomas with the 
poorest differentiation scores, 
but no change was observed 
in carcinoma–adjacent tissues. 
One-way ANOVA (Kruskal–
Wallis test with Dunn’s multiple 
comparisons) *p < 0.05
Cancer Immunology, Immunotherapy 
1 3
decrease in expression may be driven by soluble tumour fac-
tors and contribute to immunosuppression [29].
Horie and colleagues report greater HLA-DR expression 
in less well differentiated CRC carcinomas, although only 
ten carcinomas were examined [30]. We observed that HLA-
DR expression was highest in poorly differentiated stage II 
carcinomas; however, no difference was observed in the late-
stage CRC cohort.
We observed a progressive loss of HLA-DR as CRC 
developed from adenomas, which was also reported in other 
studies [24, 31]. This contrasts the findings of Sconnochia 
and colleagues (2014) who describe a greater percentage 
of MHC class II positive cells in CRC tissue, compared to 
adenomas or normal adjacent tissue [19]. This disparity 
may be explained by the different respective specificities of 
antibodies used and scoring methods employed, as outlined 
previously. In addition, our observed reduction of HLA-DR 
upon CRC progression from adenoma to carcinoma reflects 
the loss of the HLA-DR molecule itself but may also indi-
cate a loss of the factors driving HLA upregulation or cell 
surface maintenance. Gene alterations occurring during 
Table 3  Results of cox regression (multivariate analysis) on late-
stage cohort
Bolded p values < 0.05 were deemed statistically significant
–Indicates no HR or CI reported during statistical analysis when 
p > 0.05
HR hazard ratio, CI confidence interval
Parameter HR CI p value
Differentiation moderate 2.3 1.2–4.5 0.012
Differentiation poor 4.5 2–10.4 0.0001
Carcinoma size (cm) 1.14 1.01–1.3 0.031
T stage 4 2 1.13–3.5 0.017
Node stage 1 (0–2) – – 0.32
Node stage 2 (0–2) – – 0.073
Node stage 1b – – 0.437
Node stage 2a – – 0.077
Node stage 2b – – 0.584
HLA (normal epithelium) – – 0.664
HLA (normal stroma) – – 0.277
HLA (carcinoma epithelium) – – 0.99
HLA (carcinoma stroma) – – 0.89
No. of nodes – – 0.584
Fig. 5  HLA-DR expression is 
associated with longer overall 
survival when measured in 
carcinoma–adjacent epithelium 
and stroma, but not in carci-
noma compartments. A cohort 
of n = 77 stage II CRC patient 
specimens were segregated 
into HLA-DR high or low 
populations based on median 
expression level, and differences 
in survival time were assessed 
by log rank (Mantel–Cox) test, 
in tissue epithelium and stroma. 
The HLA-DRhigh cohort showed 
a longer survival time compared 
to HLA-DRlow populations, in 
carcinoma–adjacent normal 
colorectal epithelium (a) and 
stroma (b), but no differ-
ence was observed within the 
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cancer development can negatively regulate HLA expression 
[32, 33], for example damage to the class II transactivator 
(CIITA) gene, or large chromosomal deletions, as observed 
in diffuse large B cell lymphomas originating from immune-
privileged sites [34]. Many inflammatory factors drive HLA-
DR upregulation, such as cytokines, hormones and cell sur-
face chaperones, which regulate HLA-DR expression on the 
cell surface [32]. Future mechanistic studies should identify 
and examine whether specific inflammatory mediators can 
drive and maintain HLA-DR expression in CRC tissue (at 
least in the absence of genetic changes), which could direct 
the development of improved targeted therapies [33].
Immunosurveillance protects the body against the 
development of cancer, as well as pathogenic threat, and 
immunodeficiency is associated with increased carcinoma 
incidence [35]. The link between HLA-DR expression in 
many gastrointestinal carcinomas and improved survival is 
thought to reflect effective anti-carcinoma immune involve-
ment, i.e. activation of a robust adaptive T cell response. 
Other immune factors linked with favourable clinical out-
comes and clinical response to immunotherapy include T 
helper  (TH)1-associated genes, CD8 T cells, γδ T cells and 
memory T cells [3, 4, 36, 37]. Since HLA-DR mediated 
antigen presentation is critical for priming  CD4+ T cell 
effector functions, HLA-DR can also be considered to be 
an integral, upstream part of this anti-carcinoma,  TH1 axis, 
suggesting that future studies may benefit from inclusion of 
HLA-DR into prognostic scoring panels. HLA-DR can also 
be expressed by lymphocytes as an activation marker, and 
elevated expression has also been shown to predict patient 
response to neo-adjuvant treatment in the breast cancer set-
ting, further demonstrating the usefulness of this molecule 
[38].
Whether HLA-DR expression by tumour cells results in 
effective antigen presentation to T cells is unclear, but stud-
ies have shown that epithelial cells expressing HLA-DR are 
capable of antigen presentation [7] and cross-presentation 
of tumour-associated antigens by HLA-DR has been hypoth-
esised [32]. Scarlett and colleagues show that significant 
dysfunction in dendritic cells (including MHC class II 
loss) drives cancer development and metastasis in a mouse 
model of inducible human cervical cancer [39]. Interest-
ingly, T cells in this model retained the ability to recog-
nise and respond to antigenic stimuli, even at late cancer 
stages, whereas dendritic cells become dysfunctional upon 
cancer progression. These observations highlight the criti-
cal importance of effective antigen presentation for control 
of carcinoma progression, suggesting that T cell priming, a 
key step in the cancer-immune set point [40], may be just as 
important as traditional immune checkpoints [41]. Indeed, 
HLA-DR may itself represent an important and currently 
underutilised immunotherapeutic target.
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